Clinical Trial

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

Study acronym: TAUGLIP-DM2

Recruiting Phase 2

Record status

This record was last updated September 19, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Summary

Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2021-04-30; most recent amendment 2025-09-15.

Status change: Not Yet Recruiting → Recruiting 2022-01-21

Trial Details

NCT Number	NCT04874012
Lead Sponsor	Hospital de Clinicas de Porto Alegre
Conditions	Diabetes Mellitus, Type 2
Enrollment	94 participants
Start Date	2021-06-12
Primary Completion	2025-10 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-19